Cargando…
Fondaparinux versus Enoxaparin - Which is the Best Anticoagulant for Acute Coronary Syndrome? - Brazilian Registry Data
BACKGROUND: Recent studies have shown fondaparinux's superiority over enoxaparin in patients with non-ST elevation acute coronary syndrome (ACS), especially in relation to bleeding reduction. The description of this finding in a Brazilian registry has not yet been documented. OBJECTIVE: To comp...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sociedade Brasileira de Cardiologia - SBC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5053192/ https://www.ncbi.nlm.nih.gov/pubmed/27579543 http://dx.doi.org/10.5935/abc.20160127 |
_version_ | 1782458364749414400 |
---|---|
author | Soeiro, Alexandre de Matos Silva, Pedro Gabriel Melo de Barros e Roque, Eduardo Alberto de Castro Bossa, Aline Siqueira César, Maria Cristina Simões, Sheila Aparecida Okada, Mariana Yumi Leal, Tatiana de Carvalho Andreucci Torres Pedroti, Fátima Cristina Monteiro de Oliveira Jr., Múcio Tavares |
author_facet | Soeiro, Alexandre de Matos Silva, Pedro Gabriel Melo de Barros e Roque, Eduardo Alberto de Castro Bossa, Aline Siqueira César, Maria Cristina Simões, Sheila Aparecida Okada, Mariana Yumi Leal, Tatiana de Carvalho Andreucci Torres Pedroti, Fátima Cristina Monteiro de Oliveira Jr., Múcio Tavares |
author_sort | Soeiro, Alexandre de Matos |
collection | PubMed |
description | BACKGROUND: Recent studies have shown fondaparinux's superiority over enoxaparin in patients with non-ST elevation acute coronary syndrome (ACS), especially in relation to bleeding reduction. The description of this finding in a Brazilian registry has not yet been documented. OBJECTIVE: To compare fondaparinux versus enoxaparin in in-hospital prognosis of non-ST elevation ACS. METHODS: Multicenter retrospective observational study. A total of 2,282 patients were included (335 in the fondaparinux group, and 1,947 in the enoxaparin group) between May 2010 and May 2015. Demographic, medication intake and chosen coronary treatment data were obtained. Primary outcome was mortality from all causes. Secondary outcome was combined events (cardiogenic shock, reinfarction, death, stroke and bleeding). Comparison between the groups were done through Chi-Square test and T test. Multivariate analysis was done through logistic regression, with significance values defined as p < 0.05. RESULTS: With regards to treatment, we observed the performance of a percutaneous coronary intervention in 40.2% in the fondaparinux group, and in 35.1% in the enoxaparin group (p = 0.13). In the multivariate analysis, we observed significant differences between fondaparinux and enoxaparin groups in relation to combined events (13.8% vs. 22%. OR = 2.93, p = 0.007) and bleeding (2.3% vs. 5.2%, OR = 4.55, p = 0.037), respectively. CONCLUSION: Similarly to recently published data in international literature, fondaparinux proved superior to enoxaparin for the Brazilian population, with significant reduction of combined events and bleeding. |
format | Online Article Text |
id | pubmed-5053192 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Sociedade Brasileira de Cardiologia - SBC |
record_format | MEDLINE/PubMed |
spelling | pubmed-50531922016-10-07 Fondaparinux versus Enoxaparin - Which is the Best Anticoagulant for Acute Coronary Syndrome? - Brazilian Registry Data Soeiro, Alexandre de Matos Silva, Pedro Gabriel Melo de Barros e Roque, Eduardo Alberto de Castro Bossa, Aline Siqueira César, Maria Cristina Simões, Sheila Aparecida Okada, Mariana Yumi Leal, Tatiana de Carvalho Andreucci Torres Pedroti, Fátima Cristina Monteiro de Oliveira Jr., Múcio Tavares Arq Bras Cardiol Original Articles BACKGROUND: Recent studies have shown fondaparinux's superiority over enoxaparin in patients with non-ST elevation acute coronary syndrome (ACS), especially in relation to bleeding reduction. The description of this finding in a Brazilian registry has not yet been documented. OBJECTIVE: To compare fondaparinux versus enoxaparin in in-hospital prognosis of non-ST elevation ACS. METHODS: Multicenter retrospective observational study. A total of 2,282 patients were included (335 in the fondaparinux group, and 1,947 in the enoxaparin group) between May 2010 and May 2015. Demographic, medication intake and chosen coronary treatment data were obtained. Primary outcome was mortality from all causes. Secondary outcome was combined events (cardiogenic shock, reinfarction, death, stroke and bleeding). Comparison between the groups were done through Chi-Square test and T test. Multivariate analysis was done through logistic regression, with significance values defined as p < 0.05. RESULTS: With regards to treatment, we observed the performance of a percutaneous coronary intervention in 40.2% in the fondaparinux group, and in 35.1% in the enoxaparin group (p = 0.13). In the multivariate analysis, we observed significant differences between fondaparinux and enoxaparin groups in relation to combined events (13.8% vs. 22%. OR = 2.93, p = 0.007) and bleeding (2.3% vs. 5.2%, OR = 4.55, p = 0.037), respectively. CONCLUSION: Similarly to recently published data in international literature, fondaparinux proved superior to enoxaparin for the Brazilian population, with significant reduction of combined events and bleeding. Sociedade Brasileira de Cardiologia - SBC 2016-09 /pmc/articles/PMC5053192/ /pubmed/27579543 http://dx.doi.org/10.5935/abc.20160127 Text en http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Soeiro, Alexandre de Matos Silva, Pedro Gabriel Melo de Barros e Roque, Eduardo Alberto de Castro Bossa, Aline Siqueira César, Maria Cristina Simões, Sheila Aparecida Okada, Mariana Yumi Leal, Tatiana de Carvalho Andreucci Torres Pedroti, Fátima Cristina Monteiro de Oliveira Jr., Múcio Tavares Fondaparinux versus Enoxaparin - Which is the Best Anticoagulant for Acute Coronary Syndrome? - Brazilian Registry Data |
title | Fondaparinux versus Enoxaparin - Which is the Best Anticoagulant for
Acute Coronary Syndrome? - Brazilian Registry Data |
title_full | Fondaparinux versus Enoxaparin - Which is the Best Anticoagulant for
Acute Coronary Syndrome? - Brazilian Registry Data |
title_fullStr | Fondaparinux versus Enoxaparin - Which is the Best Anticoagulant for
Acute Coronary Syndrome? - Brazilian Registry Data |
title_full_unstemmed | Fondaparinux versus Enoxaparin - Which is the Best Anticoagulant for
Acute Coronary Syndrome? - Brazilian Registry Data |
title_short | Fondaparinux versus Enoxaparin - Which is the Best Anticoagulant for
Acute Coronary Syndrome? - Brazilian Registry Data |
title_sort | fondaparinux versus enoxaparin - which is the best anticoagulant for
acute coronary syndrome? - brazilian registry data |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5053192/ https://www.ncbi.nlm.nih.gov/pubmed/27579543 http://dx.doi.org/10.5935/abc.20160127 |
work_keys_str_mv | AT soeiroalexandredematos fondaparinuxversusenoxaparinwhichisthebestanticoagulantforacutecoronarysyndromebrazilianregistrydata AT silvapedrogabrielmelodebarrose fondaparinuxversusenoxaparinwhichisthebestanticoagulantforacutecoronarysyndromebrazilianregistrydata AT roqueeduardoalbertodecastro fondaparinuxversusenoxaparinwhichisthebestanticoagulantforacutecoronarysyndromebrazilianregistrydata AT bossaalinesiqueira fondaparinuxversusenoxaparinwhichisthebestanticoagulantforacutecoronarysyndromebrazilianregistrydata AT cesarmariacristina fondaparinuxversusenoxaparinwhichisthebestanticoagulantforacutecoronarysyndromebrazilianregistrydata AT simoessheilaaparecida fondaparinuxversusenoxaparinwhichisthebestanticoagulantforacutecoronarysyndromebrazilianregistrydata AT okadamarianayumi fondaparinuxversusenoxaparinwhichisthebestanticoagulantforacutecoronarysyndromebrazilianregistrydata AT lealtatianadecarvalhoandreuccitorres fondaparinuxversusenoxaparinwhichisthebestanticoagulantforacutecoronarysyndromebrazilianregistrydata AT pedrotifatimacristinamonteiro fondaparinuxversusenoxaparinwhichisthebestanticoagulantforacutecoronarysyndromebrazilianregistrydata AT deoliveirajrmuciotavares fondaparinuxversusenoxaparinwhichisthebestanticoagulantforacutecoronarysyndromebrazilianregistrydata |